Human VEGF ELISA Test Kit.

Thursday, 07/10/2010  |   Prostate Cancer  |  no comments

Vascular endothelial growth factor (VEGF) is a cytokine that plays an important role in tumour angiogenesis. VEGF is over-expressed in many human cancers, including prostate cancer, but circulating levels of VEGF in patients with prostate cancer have not been reported. In this study, we analysed plasma concentrations of VEGF in a cohort of patients with prostate cancer and compared them with a normal population.

Median plasma VEGF was 28.5 pg/mL (interquartile range 19.3 to 57.0) in patients with metastases; 7.0 pg/mL (interquartile range 0 to 26.5) in patients with localised disease, and 0 pg/mL (interquartile range 0 to 24) in controls. These differences were statistically significant (P <0.001). When compared group by group, the metastatic group had significantly higher plasma VEGF than the localised disease group and the control group (P = 0.003 and P <0.001, respectively). There was a tendency for plasma VEGF to be higher in the localised disease group than in the control group, a trend that almost reached statistical significance (P = 0.038). Using a cutoff of 18 pg/mL, the sensitivity and specificity of the test in differentiating between patients with and without metastatic disease was 81% and 71%, respectively. The odds of metastatic disease were almost 10 times greater for patients with VEGF values greater than 18 pg/mL than for those with values less than 18 pg/mL. There was no correlation between age and plasma VEGF values or between plasma VEGF and serum prostate-specific antigen (PSA). However, patients with serum PSA greater than 20 ng/mL had significantly higher plasma VEGF values than patients with serum PSA less than 20 ng/mL (P <0.001). No direct relation was found between Gleason sum and plasma VEGF, although VEGF levels were higher in patients with Gleason sums of 8 to 10 than in patients with lower Gleason sums. The study indicates that patients with metastatic prostate cancer have higher plasma VEGF levels than patients with localised disease or healthy controls. A larger prospective study is needed to confirm the predictive utility of VE
Duqueace, J.L.F., Loughlince, K.R., Adam, R.M., Kantoff, P.W., Zurakowski, D. & Freeman, M.R.

Leave a Reply

You must be logged in to post a comment.